Business Wire

CA-FORESCOUT-TECH

24.1.2023 19:01:59 CET | Business Wire | Press release

Share
Forescout Appoints Technology Veteran Barry Mainz as CEO

Forescout Technologies Inc., the global leader in compliance and cybersecurity for all connected devices, today announced that Barry Mainz will join the company as CEO, effective immediately.

Barry Mainz brings more than 25 years of experience in executive leadership across infrastructure software and cybersecurity companies. Mainz has served as CEO and member of the Board of Directors for MobileIron and also led Wind River Systems, a division of Intel, as President during important years of growth. Additionally, Mainz has held leadership roles, as well as advisory and board positions at private and public companies such as Mercury Interactive, Makara (acquired by Red Hat, Inc.) and Sun Microsystems.

“Barry has been working with Wael, our Board and myself for the last several months as we prepared to execute our next stage of growth. Barry is a passionate and inspirational leader who delivers customer value, builds strong teams and drives operational discipline and rigor,” said Greg Clark, Chairman of the Board, Forescout and former CEO of cybersecurity companies BlueCoat and Symantec. “His experience across scaled and innovative companies makes him an ideal leader to take the company to the next level. Barry rounds out a fantastic team at Forescout and will be building on our strong foundation. We are pleased with the results of Forescout’s journey to date, and we are excited about the new value Forescout is bringing to our customers through our acquisitions as well as our organic development.”

Bryan Taylor, head of Advent’s technology investment team and a Managing Partner in Palo Alto added, “We are excited for Barry’s appointment as CEO as he brings a wealth of experience and expertise to the role, and we are confident that under his leadership, the company will continue to thrive and achieve even greater success. We also want to thank Wael Mohamed for his leadership and his significant contribution to Forescout.”

“I am really excited about the work we’ve done to plan Forescout’s next horizon and am thrilled to partner with our Board, our strong management team and employees as we execute our plans,” said Barry Mainz, CEO, Forescout. “Working together with Greg and our Board over the past few months gives me high confidence that we are on the right strategy and will deliver immense value to our customers.”

About Forescout

Forescout Technologies, Inc. delivers compliance and cybersecurity for all connected devices, including IT, IoT, OT, IoMT, and cloud environments. The Forescout Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com

Managing cyber risk, together.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005897/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Linnea Achieves CEP Certification for Cannabidiol Isolate3.3.2026 08:25:00 CET | Press release

Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an active pharmaceutical ingredient (API) is adequately controlled by the monographs of the European Pharmacopoeia, ensuring its safety, quality and conformity for use in medicinal products in Europe. Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), the CEP represents an independent validation of consistency, safety, and regulatory compliance for the European market. This consequently simplifies the marketing authorization (MA) process for new medicines, as a detailed evaluation of the active substance by regulatory authorities is not required. This milestone represents a significant achievement for the company and reinforces its commitment to delivering consistent and high-quality cannabinoid ingredients. The certification provides customers and partners with as

Quectel Introduces FGH200M Wi-Fi HaLow Module for massive IoT Deployments3.3.2026 08:00:00 CET | Press release

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FGH200M long range, low power Wi-Fi HaLow module. Based on the Morse Micro MM8108 chipset and operating in the sub-1GHz license exempt frequency band, the module delivers enhanced penetration and broader coverage, over a range of approximately 1km, while supporting low power consumption and large-scale device connectivity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302200601/en/ Quectel introduces FGH200M Wi-Fi HaLow module for massive IoT deployments The FGH200M module adopts the IEEE 802.11ah wireless networking protocol, also known as Wi-Fi HaLow, operating in the license-exempt Sub-1GHz spectrum. Designed to meet the evolving requirements of IoT connectivity, the FGH200M delivers extended Sub-1GHz signal coverage, enabling reliable device control at distances of up to one kilometer. “We’re excited to unveil th

Quectel Expands Small Cell Antennas Portfolio With Five New Products3.3.2026 08:00:00 CET | Press release

Quectel Wireless Solutions, a global end-to-end IoT solutions provider, has introduced five new small cell antennas to add further functionality and provide greater flexibility and choice for customers designing and implementing small cell deployments. The new antennas bring an additional range of form factors, mounting options and performance characteristics to the Quectel antenna range. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302915004/en/ Quectel expands small cell antennas portfolio with five new products “Whether you’re looking for an antenna to support critical wireless communications, dense stadium usage scenarios or ultimate capacity, these five new Quectel antennas have been designed to meet your needs,” says David Wei, Antenna Product Head, Quectel Wireless Solutions. “The new antennas augment our already comprehensive range of antennas, bring further choice and add capabilities for developers and enginee

Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 02:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde

IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 22:15:00 CET | Press release

IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye